stockrowPhibro Animal Health Corporation
PAHC Healthcare Drug Manufacturers Specialty & Generic
Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025.
- Revenue
- +6.29%
- EPS
- +12.3%
- Free cash flow
- +262.1%
- Total debt
- −1.09%
Quarter to September 2026, against a year earlier
Follow PAHC
Alert me
Phibro Animal Health Corporation (PAHC) EV/Sales
As of 5 November 2026, Phibro Animal Health Corporation (PAHC) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from 0.8× (November 2023) to 2.9× (August 2018); the current reading is higher than 33% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.3× | (2.01%) |
| FY2025 | 1.3× | 23.74% |
| FY2024 | 1.0× | 7.76% |
| FY2023 | 1.0× | (18.14%) |
| FY2022 | 1.2× | (32.72%) |
| FY2021 | 1.8× | 3.77% |
| FY2020 | 1.7× | (7.70%) |
| FY2019 | 1.8× | (28.74%) |
| FY2018 | 2.6× | 14.56% |
| FY2017 | 2.3× | 61.35% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.4× | 7.65% |
| Jun 2026 | 1.3× | (34.47%) |
| Mar 2026 | 1.9× | 30.43% |
| Dec 2025 | 1.5× | (9.68%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PAHC Phibro Animal Health Corporation | 1.4× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.6× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 2.0× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.5× |
| CRON Cronos Group Inc. compare | 3.0× |
| XERS Xeris Biopharma Holdings, Inc. compare | 6.7× |
| ALVO Alvotech compare | 8.6× |
| ETON Eton Pharmaceuticals, Inc. compare | 9.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)